Skip to Main Content

Paper Details

High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS.
Neurology
106
2017
Author NameAffiliation
Michael K RackeFrom the Colorado Blood Cancer Institute (R.A.N.), Denver Baylor College of Medicine (G.J.H.), TX Ohio State University (M.K.R., Columbus MD Anderson Cancer Research Center (U.P.), Inc. (K.C.S.), NC National Institute of Allergy and Infectious Diseases (L.M.G.), National Institutes of Health, Imperial College London, UK City of Hope National Medical Center (H.O.), University of California San Francisco University of Texas Southwestern (O.S.), McGill University, Canada Fred Hutchinson Cancer Research Center (G.E.G.), University of Washington (M.H.W., G.H.K.) and Swedish Hospital Medical Center (J.D.B.)
James D BowenFrom the Colorado Blood Cancer Institute (R.A.N.), Denver Baylor College of Medicine (G.J.H.), TX Ohio State University (M.K.R., Columbus MD Anderson Cancer Research Center (U.P.), Inc. (K.C.S.), NC National Institute of Allergy and Infectious Diseases (L.M.G.), National Institutes of Health, Imperial College London, UK City of Hope National Medical Center (H.O.), University of California San Francisco University of Texas Southwestern (O.S.), McGill University, Canada Fred Hutchinson Cancer Research Center (G.E.G.), University of Washington (M.H.W., G.H.K.) and Swedish Hospital Medical Center (J.D.B.)
  • 1 - 2

Datasets